Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

HA-1–targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation

Blood (2024) 144 (10): 1069–1082.

https://doi.org/10.1182/blood.2024024105

Published: 2024

Includes: Supplemental data

Journal Articles

Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel

Aya Albittar, Jenna M Voutsinas, Andrew J Portuguese, Jennifer J. Huang, Emily C Liang, Qian Wu, Xinyi Fan, Alexandre V Hirayama, Erik L Kimble, Lorenzo Iovino, Christina Poh, Ajay K Gopal, Mazyar Shadman, Brian G Till, Filippo Milano, Aude G Chapuis, Ryan D Cassaday, David G Maloney, Jordan Gauthier

Blood (2023) 142 (Supplement 1): 2126.

https://doi.org/10.1182/blood-2023-180128

Published: 2023

Journal Articles

Elevated Metabolite Secretion Facilitates a Treg-Mediated Immunosuppressive Microenvironment in the Solid Tumor

Sinéad Kinsella, Colton W Smith, Kelly McKenna, Menna Hailemariam, Francesco Mazziotta, Lauren E Martin, Shihong Zhang, Tzu-Hao Tang, Jonathan Linton, Thomas M Schmitt, Anthony Rongvaux, Aude G Chapuis

Blood (2023) 142 (Supplement 1): 3458.

https://doi.org/10.1182/blood-2023-189868

Published: 2023

Journal Articles

Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis

Blood (2023) 142 (Supplement 1): 6848.

https://doi.org/10.1182/blood-2023-172695

Published: 2023

Journal Articles

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 2143.

https://doi.org/10.1182/blood-2023-174106

Published: 2023

Journal Articles

Day +3/Day 0 Ferritin Ratio: A Simple Point-of-Care Index Predictive of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome after CD19 CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 3495.

https://doi.org/10.1182/blood-2023-182597

Published: 2023

Journal Articles

Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting

Andrew J Portuguese, Aya Albittar, Emily C Liang, Jennifer J. Huang, Alexandre V Hirayama, Erik L Kimble, Lorenzo Iovino, Christina Poh, Ajay K Gopal, Mazyar Shadman, Brian G Till, Hans-Peter Kiem, Filippo Milano, Aude G Chapuis, Folashade Otegbeye, Ryan D Cassaday, David G Maloney, Jordan Gauthier

Blood (2023) 142 (Supplement 1): 2131.

https://doi.org/10.1182/blood-2023-172978

Published: 2023

Journal Articles

Impact of “Cell-of-Origin” on Outcome after Axicabtagene-Ciloleucel CAR-T Cell Therapy in Relapsed/Refractory Aggressive Non-Hodgkin B-Cell Lymphomas

Ilaria Romano, Jordan Gauthier, Ryan C Lynch, Ajay K Gopal, Alexandre V Hirayama, Kikkeri N Naresh, Alireza Torabi, Stephen D Smith, Brian G Till, David G Maloney, Chaitra S Ujjani, Christina Poh, Filippo Milano, Aude G Chapuis, Mazyar Shadman, Lorenzo Iovino

Blood (2023) 142 (Supplement 1): 2137.

https://doi.org/10.1182/blood-2023-181956

Published: 2023

Journal Articles

Phase 2 Study of CD19 CAR T Cells with a Fully Human Binder for Large B-Cell Lymphoma in Relapse or Progression after a Murine Binder-Bearing CD19 CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 6860.

https://doi.org/10.1182/blood-2023-181273

Published: 2023

Journal Articles

Leukemia Blasts Induce NK-like Dysfunction in AML-Specific T Cells

Francesco Mazziotta, Lauren E Martin, Miranda Lahman, Daniel N. Egan, Sinéad Kinsella, Kelly Paulson, Yapeng Su, Valentin Voillet, Livius Penter, Catherine J Wu, Philip Greenberg, Aude G Chapuis

Blood (2023) 142 (Supplement 1): 4849.

https://doi.org/10.1182/blood-2023-189773

Published: 2023

Journal Articles

Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Alexandre Vinaud Hirayama, Salvatore Fiorenza, Jordan Gauthier, Jenna M. Voutsinas, Qian Vicky Wu, Erik L. Kimble, Barbara S. Pender, Delaney R. Kirchmeier, Henna A. Di, Ryan D. Cassaday, Aude G. Chapuis, Damian J. Green, Hans-Peter Kiem, Filippo Milano, Mazyar Shadman, Brian G. Till, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle

Blood (2022) 140 (Supplement 1): 7447–7449.

https://doi.org/10.1182/blood-2022-168185

Published: 2022

Journal Articles

Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Andrew J. Cowan, Margot Pont, Blythe Duke Sather, Cameron J. Turtle, Brian G. Till, Edward Libby, David G. Coffey, Sherilyn A. Tuazon, Brent L. Wood, Ted A Gooley, Qian Vicky Wu, Mazyar Shadman, Jordan Gauthier, Aude G. Chapuis, Filippo Milano, David G. Maloney, Stanley R. Riddell, Damian J. Green

Blood (2021) 138 (Supplement 1): 551.

https://doi.org/10.1182/blood-2021-154170

Published: 2021

Journal Articles

Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL

Blood (2021) 138 (Supplement 1): 3872.

https://doi.org/10.1182/blood-2021-149181

Published: 2021

Journal Articles

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

Blood (2021) 137 (3): 323–335.

https://doi.org/10.1182/blood.2020006770

Published: 2021

Includes: Supplemental data

Journal Articles

Addressing Relapsed Disease Following Cellular Therapy

Aude G. Chapuis, MD

Blood (2020) 136 (Supplement 1): SCI1.

https://doi.org/10.1182/blood-2020-133094

Published: 2020

Journal Articles

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-136440

Published: 2020

Journal Articles

Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells

Evandro D. Bezerra, MD, Jordan Gauthier, MD MSc, Alexandre V. Hirayama, MD, Barbara S. Pender, MSc, Reed M. Hawkins, BS, Aesha Vakil, MSc, Rachel N. Steinmetz, BS, Aude G. Chapuis, MD, Brian G. Till, MD, Hans-Peter Kiem, MD PhD, Mazyar Shadman, MD MPH, Ryan D. Cassaday, MD, Stanley R. Riddell, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD

Blood (2019) 134 (Supplement_1): 201.

https://doi.org/10.1182/blood-2019-123807

Published: 2019

Journal Articles

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

Blood (2019) 133 (17): 1876–1887.

https://doi.org/10.1182/blood-2018-11-887067

Published: 2019

Includes: Supplemental data

Journal Articles

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy

Blood (2019) 133 (15): 1652–1663.

https://doi.org/10.1182/blood-2018-11-883710

Published: 2019

Includes: Supplemental data

Journal Articles

Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma

Jordan Gauthier, MD, Alexandre V. Hirayama, MD, Kevin A. Hay, MDFRCPC, MSc, Alyssa Sheih, PhD, Barbara S. Pender, MSc, Reed M. Hawkins, BS, Aesha Vakil, MSc, Tinh-Doan Phi, BS, Rachel N. Steinmetz, BS, Aude G. Chapuis, MD, Brian G. Till, MD, Hans-Peter Kiem, MD PhD, Mazyar Shadman, Ryan D. Cassaday, MD, Utkarsh H. Acharya, DO, Stanley R. Riddell, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD

Blood (2018) 132 (Supplement 1): 1415.

https://doi.org/10.1182/blood-2018-99-111528

Published: 2018

NARROW

HA-1–targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation

Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel

Elevated Metabolite Secretion Facilitates a Treg-Mediated Immunosuppressive Microenvironment in the Solid Tumor

Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Day +3/Day 0 Ferritin Ratio: A Simple Point-of-Care Index Predictive of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome after CD19 CAR T-Cell Therapy

Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting

Impact of “Cell-of-Origin” on Outcome after Axicabtagene-Ciloleucel CAR-T Cell Therapy in Relapsed/Refractory Aggressive Non-Hodgkin B-Cell Lymphomas

Phase 2 Study of CD19 CAR T Cells with a Fully Human Binder for Large B-Cell Lymphoma in Relapse or Progression after a Murine Binder-Bearing CD19 CAR T-Cell Therapy

Leukemia Blasts Induce NK-like Dysfunction in AML-Specific T Cells

Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

Addressing Relapsed Disease Following Cellular Therapy

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy

Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only